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ABSTRACT
The overall survival of lung cancer patients remains dismal despite the availability 
of targeted therapies. Oncofetal protein SALL4 is a novel cancer target. We herein 
report that SALL4 was aberrantly expressed in a subset of lung cancer patients with 
poor survival. SALL4 silencing by RNA interference or SALL4 peptide inhibitor treatment 
led to impaired lung cancer cell growth. Expression profiling of SALL4-knockdown 
cells demonstrated that both the EGFR and IGF1R signaling pathways were affected. 
Connectivity Map analysis revealed the HDAC inhibitor entinostat as a potential drug in 
treating SALL4-expressing cancers, and this was confirmed in 17 lung cancer cell lines. 
In summary, we report for the first time that entinostat can target SALL4-positive lung 
cancer. This lays the foundation for future clinical studies evaluating the therapeutic 
efficacy of entinostat in SALL4-positive lung cancer patients.
INTRODUCTION
Lung cancer is the leading cause of cancer deaths in 
both men and women in the United States and worldwide. 
It can be divided into small cell lung cancer (~20%) and 
non-small cell lung cancer (NSCLC, ~80%)[1]. Major 
treatment options for NSCLC, depending on the stages of 
disease, include surgery, radiation, and platinum doublet 
chemotherapy. In the past decade, the discovery of EGFR 
mutations and EML4-ALK fusions has led to advances in 
the treatment of NSCLC through the use of targeted therapies 
[2–4]. While other driver mutations, including HER2, MET, 
NRAS, BRAF, FGFR1, PIK3CA, AKT1, RET, and ROS1 may 
represent viable therapeutic targets, overall they occur only at 
low frequency in NSCLC, with more than 50% of cases still 
lacking defined driver mutation [5–9]. Therefore, therapeutic 
options are still limited for many advanced NSCLC patients. 
In addition, acquired resistance to the existing targeted agents 
and disease recurrence present further challenges and highlight 
the urgent need for alternative treatment strategies [10, 11].
SALL4 is well established to be one of the critical 
stem cell factors for the maintenance of pluripotency and 
self-renewal of embryonic stem cells (ESCs)[12, 13]. 
Aberrant SALL4 expression has been reported in acute 
myeloid leukemia (AML) and a panel of solid tumors, 
including hepatocellular carcinoma (HCC), gastric cancer, 
and endometrial cancer [14–19]. Targeting SALL4 as a 
potential therapeutic strategy has been demonstrated in 
AML and HCC by interrupting the interaction between 
SALL4 and the histone deacetylase (HDAC) complex [15, 
16]. Aberrant SALL4 expression in lung cancer patients 
has been reported, and the detection of SALL4 mRNA 
expression has been proposed as a diagnostic marker for 
lung cancer patients [20, 21]. However, the functional 
role(s) of SALL4 in NSCLC and its related mechanism, as 
well as its therapeutic potential in lung cancer still remain 
unknown. To answer these questions, we first examined 
the oncogenic role of aberrant SALL4 protein expression 
in human NSCLC. The follow-up mechanistic studies 
demonstrated that SALL4 affected both the EGFR and 
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IGF1R signaling pathways by suppressing the expression 
of one of the E3 ubiquitin-protein ligases, CBL-B, 
probably through its reported interaction with the HDAC 
complex. Notably, our preclinical data indicates that the 
SALL4-expressing lung cancer cells were more sensitive 
to the histone deacetylase inhibitor (HDACi) entinostat 
(MS-275) treatment, suggesting that lung cancer patients 
with SALL4 overexpression may benefit from treatment 
with entinostat.
RESULTS
Aberrant SALL4 expression is detected in 
a subset of lung cancer and high SALL4 
expression is correlated with poor survival
To determine whether SALL4 is aberrantly expressed 
in lung cancer, we performed immunohistochemistry 
(IHC) to analyze the protein expression level of SALL4 
in a cohort of lung cancer patients from the archives of 
the National University Hospital, Singapore, with normal 
lung tissues serving as control. Table 1  illustrates the 
demographic and clinicopathological characteristics of 
these patients. We observed elevated SALL4 expression in 
a subset of lung cancer patients compared to normal lung 
tissues (Figure 1a). Among non-small cell lung cancers 
(NSCLCs), 16.2% were positive for SALL4 expression. 
Within the NSCLC cases, SALL4 was found to be positive 
in 12% of adenocarcinomas (ADC) (n=100), 19% of 
adenocarcinoma in situ (n=21) and 23% of squamous 
cell carcinoma (SCC) (n=52). In addition, we evaluated 
RNA expression of SALL4 in paired tumor and normal 
tissues from 12 lung cancer patients. Seven of these 12 
lung cancer patients had increased SALL4 expression, 
and overall, there was a statistically significant increase 
in SALL4 expression in lung cancer tissues as compared 
to adjacent normal lung tissues (P=0.04) (Supplementary 
Figure S1).
To validate the observation from our cohort of 
primary patient samples, we utilized the published 
expression profiling data on lung cancers (Accession 
GSE31210) from the Gene Expression Omnibus (GEO) 
database [22]. SALL4 transcript level was analyzed in 
226 adenocarcinomas and 20 adjacent normal lung tissue 
samples. The expression of SALL4 was significantly 
increased in cancer tissues compared to normal controls 
(p<0.0001) (Figure 1b), confirming our observation 
from the immunohistochemistry staining. Using the 
same dataset, we further evaluated lung cancer patients 
with known mutations in EGFR, KRAS, and ALK. Lung 
cancer patients with EGFR and/or KRAS mutations 
were found to have higher SALL4 expression, while 
patients with ALK mutations did not have significantly 
higher SALL4 expression (Supplementary Figure S2). 
Table 1: Demographic and clinicopathological characteristics of lung cancer patients from the National University 
Hospital, Singapore
Demographic and clinicopathological characteristics Frequency (%)
Age (n=138)
 < median (64.33) 68 (49.3)
 > median 70 (50.7)
Gender (n=139)
 Female 41 (29.5)
 Male 98 (70.5)
Stage (n=127)
 1 75 (59.1)
 2 25 (19.7)
 3 21 (16.5)
 4 6 (4.7)
Differentiation (n=123)
 Well & moderately differentiated 79 (64.2)
 Poorly differentiated 44 (35.8)
Tumor size (n=128)
 < median (3.5cm) 56 (43.8)
 ≥ median 72 (56.2)
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Furthermore, using the same dataset, we evaluated 
the prognostic value of SALL4 expression in lung 
cancer patients. Using median expression level as the 
cutoff value, we found that high SALL4 expression in 
lung cancer was significantly correlated with reduced 
relapse-free survival and overall survival (Figure 1c), 
suggesting that patients with high SALL4 expression 
have poorer survival advantage. Similar observation 
was also seen in another cohort of samples from 
the GEO database – elevated SALL4 expression is 
observed in lung cancer patients (Accession GSE19188, 
Supplementary Figure S3a) [23]. Further analysis 
showed that there is no significant difference, in terms 
of SALL4 expression level, between different subtypes 
of NSCLCs (Supplementary Figure S3b). To investigate 
whether gene sets that have prognostic values are 
enriched in SALL4-expressing lung carcinomas, we 
carried out Gene Set Enrichment Analysis (GSEA) 
by using the GSE19188 dataset. Indeed, we observed 
enrichment of gene sets upregulated in lung cancers with 
poor survival (P < 0.001) in SALL4-expressing group. 
On the other hand, gene sets that are enriched in lung 
cancers with good survival (P < 0.001) are enriched 
in the SALL4-negative group (Supplementary Figure 
S3c). These observations were confirmed by a third 
published primary lung adenocarcinoma dataset from 
the TCGA database. SALL4 expression was significantly 
upregulated in adenocarcinoma tissues compared to the 
matched normal lung tissues (P < 0.001) (Supplementary 
Figure S3d). Comparing 61 samples with the highest 
and lowest SALL4 expression from the same dataset, we 
observed significant survival advantage for the patients 
with low SALL4 expression (P = 0.017) (Supplementary 
Figure S3d). These data collectively demonstrated that 
aberrant SALL4 expression is observed in NSCLCs and 
SALL4 has prognostic value in lung cancer.
Figure 1: Aberrant SALL4 expression in lung cancer. a. Representative SALL4 IHC images. Upper panel was taken with 100X 
magnification; lower panel was taken with 400X magnification. The left most images were from a case of adenocarcinoma with no SALL4 
expression. Second left images were from a case of adenocarcinoma with +3 SALL4 expression. Second right images were the matched 
normal sample of the right most squamous cell carcinoma case, which has +4 SALL4 expression. The enlarged regions in the lower panel 
were indicated by the black rectangular boxes in the upper panel images. b. Gene expression profiling data analysis on 226 adenocarcinomas 
and 20 adjacent normal lung tissue samples (dataset GSE31210 from the GEO database) shows that SALL4 expression is significantly 
higher in lung cancer samples compared to normal lung tissues (***P < 0.0001). c. Survival analysis demonstrates that SALL4 expression 
is significantly correlated with reduced relapse-free survival and overall survival of lung cancer patients. This analysis was done on dataset 
GSE31210 from the GEO database.
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SALL4 expression is essential for tumorigenicity 
of lung cancer cells
To investigate if SALL4 has a functional role in 
tumorigenicity of lung cancer cells, we first screened 
16 NSCLC cell lines for SALL4 expression by using 
qRT-PCR in order to select for appropriate models for 
downstream functional studies (Supplementary Figure 
S4a). ADC cell line H522 and large cell carcinoma 
(LCC) cell line H661 showed the highest SALL4 RNA 
expression level among the 16 cell lines (Supplementary 
Figure S4a), which was confirmed by immunoblotting 
at protein expression level (Supplementary Figure S4b). 
Moderate endogenous SALL4 expression was detected in 
both H292 and PC-9 cell lines, and low or undetectable 
SALL4 expression was seen in HCC827 and H1299 cells 
(Supplementary Figure S4a). Notably, H292 lung cancer 
cells have EGFR amplification while PC-9 lung cancer 
cells harbor the EGFR exon 19 deletion mutation.
Next, to investigate the functional role of SALL4 
in lung cancer, SALL4 expression was downregulated 
by lentiviral-mediated delivery of SALL4-specific short 
hairpin RNA (shRNA) to the high SALL4-expressing 
lung cancer cell lines (H661, H522, H292 and PC-9). The 
specificity of this SALL4 shRNA has been validated in our 
previous studies [15, 19]. The SALL4 shRNA transductions 
resulted in 50-90% inhibition of SALL4 expression at 
protein and mRNA levels in H661, H522, H292 and PC-9 
cell lines (Figure 2a). We evaluated the effects of SALL4 
knockdown on cell viability of these cells (Figure 2b). 
SALL4 shRNA treatment markedly reduced the number of 
viable cells compared to scramble shRNA control treatment 
(Figure 2b). Furthermore, the oncogenic role of SALL4 was 
investigated in an in vitro foci formation assay and an in 
vivo lung cancer xenograft mouse model using H661 and 
PC-9 cells with downregulated SALL4 expression (Figure 
2c–2e). SALL4 downregulation significantly impaired the 
tumorigenic potential of H661 cells in vitro (Figures 2c and 
2d). In the in vivo xenograft assay, shRNA-treated PC-9 
cells were injected subcutaneously into NOD/SCID mice 
and monitored for tumor development. SALL4 knockdown 
dramatically inhibited tumor growth compared to scramble 
shRNA control group (Figure 2e). These data suggest that 
SALL4 expression is critical for lung tumor cell growth in 
vitro and in vivo.
We have recently described a SALL4 peptide as a 
competitive inhibitor to antagonize the oncogenic function 
of SALL4 in AML [15] and HCC [15, 17]. In our present 
study, we further evaluated the anti-proliferative effects 
of this 12-amino acid peptide in SALL4-expressing lung 
cancer cell lines. Treatment with 10 μM of TAT peptide-
tagged SALL4 peptide (TAT-SALL4) led to a 30-50% 
reduction of cell viability in all three SALL4-positive 
lung cancer cell lines (H661, H522, and PC-9), while no 
effect was observed on non-SALL4-expressing H1299 
cells, compared to control peptides (TAT, or TAT-Con) 
(Supplementary Figure S5). Taken together, these data 
suggest that SALL4 has a functional role and is a feasible 
drug target in lung cancer.
Downregulation of SALL4 blocks both IGF1R 
and EGFR signaling pathways
To elucidate the potential mechanism(s) of SALL4 
in lung cancer, we performed microarray gene expression 
profiling on H661 cells treated with scramble shRNA 
control and a SALL4-specific shRNA. Combination of one-
way ANOVA analysis and pathway analysis using Pathway 
Interaction Database (PID) showed that both EGFR (P = 
1.03E-03) and IGF1R (P = 1.37E-05) signaling pathways 
were significantly affected by SALL4 downregulation. 
However, further analysis showed that SALL4 knockdown 
had little effects on the RNA expression levels of IGF1R 
and EGFR in H661 cells (Figure 3a). Nonetheless, SALL4 
depletion led to decreased protein expression of total IGF1R 
and phospho-IGF1R in H661 and H522 cell lines (Figure 
3b, left panel), as well as reduced protein expression of total 
EGFR and phospho-EGFR in H292 and PC-9 cells (Figure 
3b, right panel), despite the unchanged RNA expression 
levels. Furthermore, SALL4 knockdown also inactivated 
the IGF1R/EGFR downstream intermediate target AKT, 
as seen from downregulation of phospho-AKT, but not 
MAPK in the four lung cancer cell lines examined (Figure 
3b). These data suggest that depletion of SALL4 expression 
in lung cancer cells blocks both the EGFR and IGF1R 
signaling pathways, albeit not through direct regulation of 
EGFR and IGF1R mRNA expression.
SALL4 regulates EGFR and IGF1R signaling 
pathways through CBL-B ubiquitin ligase
It is known that receptor tyrosine kinases (RTKs), 
including EGFR and IGF1R, can be negatively regulated 
by CBL RING ubiquitin ligases [24, 25]. Interestingly, 
our microarray data showed that loss of SALL4 led to 
an upregulation of CBLB, a member of the CBL RING 
ubiquitin ligases, which was further confirmed by qRT-
PCR (Figure 4a). In addition, SALL4 knockdown induced 
CBL-B protein expression in four lung cancer cell lines 
examined (H661, H522, PC-9, and H292) (Figure 4b). 
The effects of SALL4 on CBL-B expression were further 
evaluated by western blotting after overexpression of 
SALL4 in a normal lung epithelial cell line (Beas2B). 
Ectopic expression of both SALL4 isoforms A and 
B suppressed CBL-B expression (Figure 4c). These 
results suggest that SALL4 augments EGFR and IGF1R 
expression in lung cancer through the downregulation of 
CBL-B ubiquitin ligase.
We next performed SALL4 chromatin 
immunoprecipitation (ChIP)-qPCR to investigate 
if SALL4 binds directly on the promoter region of 
CBLB, thereby repressing its expression. Significant 
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enrichment of SALL4 binding on CBLB promoter 
was observed, as compared to the isotype control 
(Figure 4d), suggesting that SALL4 might regulate 
the expression of CBL-B directly by transcription 
repression. Figure 4e shows the enrichment of SALL4 
protein in our ChIP sample.
Integrated analysis using connectivity Map 
reveals that HDAC inhibitors can reverse 
SALL4 gene expression signature in lung cancer
While we have identified a peptide to specifically 
inhibit the growth of SALL4-expressing lung cancer 
cells, the clinical utility of peptides, in general, is 
limited by their sub-optimal in vivo delivery efficiency. 
To search for potential existing drug(s) to treat SALL4-
expressing cancers, we conducted Connectivity Map 
(cMap) analysis [26, 27]. The SALL4 gene signature 
obtained from either our knockdown experiments or 
from data mining on primary lung cancer patients was 
compared to the drug signatures through the cMap 
site (http://www.broadinstitute.org/cmap/) with over 
thousands of expression profiling results upon drug 
treatments. The outcome of comparison was given a 
score from +1 (maximum positive correlation) to -1 
(maximum negative correlation) based on the extent 
of correlation between the two gene signatures. In our 
case, the drugs that received a score close to -1 are 
Figure 2: SALL4 knockdown impaired lung cancer cell viability and tumorigenicity in vitro and in vivo. a. Western blots 
show SALL4 downregulation in lung cancer cell lines H661, H522, H292 and PC-9 upon lentiviral-mediated delivery of SALL4-specific 
shRNA. b. MTT assays show reduced cell viability upon SALL4 knockdown. (Continued )
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most likely to have therapeutic values for the SALL4-
expressing lung cancer cells since the drug signatures 
are in a reverse correlation with the SALL4 gene 
signature.
We first performed cMap analysis using one set of 
SALL4 gene signature generated from the comparison 
between normal human control versus primary lung cancer 
samples (Supplementary Tables S1 and S2). A separate 
SALL4 gene signature generated from differentially 
expressed genes following SALL4 knockdown in the 
lung cancer cell line H661 (Supplementary Table S3) 
was also used by cMap. Comparative analysis identified 
overlapping of three candidate drugs in all three analyses 
using the various gene signatures (Supplementary Table 
S4). Intriguingly, entinostat (MS-275), a HDACi, was 
among the three common drugs. This, however, was not 
unexpected, as we have reported in our previous studies 
that one of the main functions of SALL4 is to act as a 
transcription repressor by interacting with the nucleosome 
remodeling and deacetylase (NuRD) complex that 
comprises of HDAC1 and HDAC2 [28]. As an HDACi, 
entinostat preferentially inhibits HDAC1 as compared to 
HDAC3 [29], and has been used in clinical trials to treat 
lung cancer patients [30].
SALL4-expressing lung cancers are sensitive to 
HDAC inhibitor entinostat treatment
To validate the cMap result, we conducted further 
studies using the HDACi entinostat. A panel of 17 
Figure 2: (Continued ) SALL4 knockdown impaired lung cancer cell viability and tumorigenicity in vitro and in vivo. 
c. Foci formation assay shows decreased foci formation when SALL4 is downregulated. d. Bar chart shows the quantitation of foci formed 
in both the Scr-sh and SALL4-sh groups. **** P < 0.0001, Student’s t test. e. SALL4 depletion inhibited tumorigenecity of lung cancer 
cells (PC-9) in vivo. Tumor volume (mm3) was measured at various time points after transplantation (n = 5). Error bars indicate standard 
error from five mice. * P < 0.05, Student’s t test. Tumor volume (mm3) was calculated by the following formula: (length × width× height)/2
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lung cancer cell lines with different expression levels 
of SALL4 was evaluated for their drug sensitivity to 
entinostat. We first noticed that lung cancer cells with 
high SALL4 expression levels such as H661 and PC-9 
cells were more sensitive to entinostat treatment than 
those with low SALL4 expression level, such as H1299 
cells. The IC50 values of entinostat at day 3 were 1.17 
μM for H661, 0.88 μM for PC-9, and 7.7 μM for H1299, 
respectively (Figure 5a). Furthermore, based on SALL4 
mRNA expression level, 17 lung cancer cell lines were 
stratified into “SALL4 high” and “SALL4 low” groups 
using the mean SALL4 expression level as threshold. 
The entinostat sensitivity was then compared between 
these two groups (Figure 5b). A negative correlation 
between the IC50 of entinostat and SALL4 expression 
level was observed, suggesting that lung cancer cells 
with high SALL4 expression were more sensitive to 
entinostat treatment (P = 0.03) (Figure 5b). To further 
evaluate the correlation between SALL4 expression and 
entinostat treatment sensitivity, SALL4 isoforms A and 
B were overexpressed in SALL4 negative lung cancer 
cell line H1299 (Figure 5c). Ectopic expression of 
Figure 3: SALL4 affects EGFR and IGF1R signaling pathways indirectly. a. qRT-PCR data shows that SALL4 knockdown 
in H661 cell line had no effect on the expression of EGFR and IGF1R at RNA levels, validated our microarray data. b. Immunoblotting 
shows that SALL4 knockdown inactivated IGF1R/EGFR signaling and their downstream mediator phospho-AKT, but not MAPK, in 
IGF1R activated H661 and H522 cell lines (left panels), and EGFR activated PC-9 and H292 cell lines (right panels), ß-actin was used as 
a loading control.
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Figure 4: SALL4 represses CBL-B, an E3 ubiquitin ligase implicated in the degradation of EGFR and IGF1R. a. qRT-
PCR data shows that SALL4 knockdown in H661 cell line induced CBLB expression at RNA levels, confirming our microarray data. 
b. SALL4 knockdown resulted in upregulation of CBL-B in four lung cancer cell lines at protein levels. c. Ectopic overexpression of 
SALL4 significantly decreased CBL-B expression in a normal lung cell line (Beas2B). d. ChIP-qPCR experiments indicate that SALL4 
binds to the CBLB promoter in H661 cells. * P < 0.05, Student’s t test. e. ChIP-WB shows enrichment of SALL4 protein in SALL4 ChIP 
sample.
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Figure 5: SALL4-expressing cells are more sensitive to HDACi entinostat treatment. a. MTT assay shows the inhibition of 
cell growth in lung cancer lines (H661, PC-9 and H1299) after 72 h treatment with HDACi entinostat at various dosage (0.78, 1.56, 3.12, 
6.25, 12.5, and 25 μM). Data were normalized to the DMSO control, and represent the mean values (± s.d.) of quadruplicate cultures from 
two independent experiments. b. IC50 values of entinostat treatment was plotted against two groups of lung cancer cell lines (n = 17) with 
high or low SALL4 expression. Entinostat sensitivity is correlated positively with SALL4 expression. c. Western blot shows overexpression 
of SALL4 isoforms A and B in the SALL4 negative lung cancer cell line H1299 d. MTT assay shows increased sensitivity of H1299 cells 
to entinostat treatment upon SALL4 overexpression when compare to FUW empty vector control (* P < 0.05). e. qRT-PCR shows CBLB 
expression in H661, PC-9, and H1299 cells after treatment with entinostat for 48 h. (Continued )
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SALL4 in these cells led to increased sensitivity of the 
cells to entinostat treatment, as indicated by a reduced 
IC50 value (Figure 5d).
Since SALL4 can repress its downstream target 
gene expression through its interaction with the HDAC-
containing complex NuRD, we reason that entinostat, an 
HDACi, can potentially affect the repressive function of 
SALL4. We have shown in this study that SALL4 can 
repress CBL-B expression in lung cancer cells. We next 
examined whether the expression of CBL-B in these cells 
was affected upon entinostat treatment. The expression 
levels of CBL-B were increased significantly only in 
SALL4-expressing H661 and PC-9 cell lines and not 
in SALL4-non-expressing H1299 cells after entinostat 
treatment (Figure 5e). Additionally, entinostat treatment 
led to a decrease in SALL4 expression levels (Figure 5f), 
and abolished the enrichment of SALL4 binding on CBLB 
promoter as observed from SALL4 ChIP-qPCR in H661 
cells (Figure 5g).
To our knowledge, these data demonstrate for the 
first time that high SALL4 expression is associated with a 
more sensitive response to entinostat treatment in human 
lung cancer cells. Therefore, SALL4 might be a good 
predictive marker for entinostat, and possibly other HDAC 
inhibitors in lung cancer.
DISCUSSION
SALL4 is an important stem cell factor [12, 13], 
and it has recently emerged as an oncofetal protein [15]. 
Aberrant SALL4 expression has been reported in a myriad 
of solid tumors including HCC [15, 16, 31], endometrial 
cancer [19], ovarian cancer [32], breast cancer [33], 
gastric cancer [18, 34], lung cancer [20, 21], and germ 
cell tumors [35–37], as well as in leukemias [14, 38, 39]. 
Its druggability has been proposed in liver cancer and 
AML [15]. Lung cancer is the leading cause of cancer 
deaths in the United States (US) and worldwide. Recently, 
molecular targeted therapies including EGFR and ALK 
inhibitors have resulted in some improvement in the 
treatment response in selected groups of NSCLC patients. 
However, EGFR and ALK aberrations collectively account 
for only approximately 15% of all NSCLCs in the US, and 
the overall survival rate for lung cancer patients remains 
extremely poor (5-year survival rate of ~15%). Therefore, 
more effective therapeutics are needed for lung cancer 
patients, particularly for the ones that are negative for 
EGFR mutations.
In our present study, we first examined SALL4 
expression in a cohort of primary lung cancer samples 
using immunohistochemical staining. 16% of 173 
Figure 5: (Continued ) SALL4-expressing cells are more sensitive to HDACi entinostat treatment. f. Western blot shows 
reduced SALL4 expression and increased CBL-B expression in H661 cells after entinostat treatment for 72 h. g. ChIP-qPCR shows 
decreased SALL4 binding to the CBLB promoter upon treatment with 10μM entinostat for 24h. n.s.: not significant
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primary lung cancer patients demonstrated positive 
SALL4 expression, whereas no expression of SALL4 
was observed in normal lung tissues (except for the basal 
layer of bronchiolar epithelium), consistent with published 
results by other groups [37, 40, 41]. The observation that 
SALL4 is overexpressed in a subgroup of lung cancers 
was further validated by analysis of published gene 
expression profiles of lung cancers in public databases. 
Importantly, we have also observed positive SALL4 
expression in EGFR mutation negative lung cancer 
patients. The correlation between SALL4 expression and 
poorer patient survival in lung cancer is consistent with 
our observations from HCC, endometrial cancer and 
myelodysplastic syndrome. The unique expression pattern 
of SALL4 in lung cancer suggests that it can potentially 
be a good drug target for personalized medicine, targeting 
the lung cancer subtypes that cannot be treated by current 
targeted therapies like EGFR and ALK inhibitors.
To date, targeted therapies have reshaped the 
management of various types of cancers including 
NSCLC. EGFR is frequently strongly activated and 
overexpressed in NSCLC. Oncogenic EGFR mutation is 
a compelling therapeutic target in NSCLCs and numerous 
agents have been developed to target this moiety [42–44]. 
However, cancer cells may circumvent the drug effects 
of EGFR inhibitors by activating alternative pathways, 
thus limiting the efficacy of such therapeutic approaches 
[45, 46]. One of these alternative pathways is the IGF1R 
pathway, which is an important cell survival pathway. In 
the setting of NSCLC, increased expression of IGF1R 
appears to be detected in up to 70% of patients [47]. 
Also IGF1R overexpression was found to correlate 
with decreased efficacy of EGFR targeting, suggesting 
the importance of IGF1R signaling in EGFR inhibitors 
drug resistance [48, 49]. All these studies suggest that 
co-targeting of both IGF1R and EGFR represent a more 
viable therapeutic option for NSCLC.
In this study, we show that depletion of SALL4 
by shRNA resulted in a decreased in cell viability and 
tumorigenicity of SALL4-positive lung cancer cells, 
which were associated with dysregulation of both EGFR 
and IGF1R signaling pathways. The regulatory effects 
of SALL4 on these two pathways seem to be indirect 
as SALL4 had no direct effect on the mRNA expression 
of EGFR/IGF1R. Instead, SALL4 silencing induced the 
expression of CBL-B, an E3 ubiquitin ligase, both at the 
protein and mRNA levels. Members of the CBL protein 
family (CBL, CBL-B and CBL-C) have emerged as 
dominant “activated RTK-selective” ubiquitin ligases, 
which serve a unique role as activation-induced feedback 
negative regulators of RTKs, including EGFR, PDGFR, 
MET, KIT, and IGF1R. Various studies have demonstrated 
that CBL protein-dependent ubiquitination targets 
activated RTKs for degradation either by promoting their 
proteasomal degradation or by facilitating their endocytic 
sorting into lysosomes. Data from lung cancer cell 
lines suggest that SALL4 downregulation may result in 
degradation of EGFR and IGF1R proteins, possibly in part 
through CBL-B. This model needs to be verified further by 
rescue experiments in the future.
We have previously identified a peptide that can 
block the oncogenic function of SALL4 by interrupting 
the interaction between SALL4 and the NuRD complex 
[15]. While the development of SALL4-specific 
inhibitor(s) that mimic this SALL4 peptide is ongoing, 
we set out to search for existing drugs that can potentially 
treat SALL4-expressing cancers. Using cMap predication, 
we identified that the drug signature from HDAC inhibitor 
entinostat significantly correlates with SALL4 gene 
signature. Using a panel of 17 lung cancer cell lines with 
varying SALL4 expression levels as a preclinical model, 
we further confirmed that high SALL4 expression lung 
cancer cells were more sensitive to entinostat treatment. 
Entinostat can induce the expression of CBLB, a gene that 
is repressed by SALL4 in lung cancer cells, representing 
a potential mechanism for the sensitivity of SALL4-
expressing lung cancer cells to this drug. entinostat is an 
HDACi targeting class I enzymes HDAC1 to HDAC3. 
Recent clinical trials conducted on patients with lung 
cancer reveal that combination of entinostat with existing 
lung cancer treatments, such as erlotinib or azacitidine, 
appears promising, particularly for the carefully selected 
subgroups of patients [30]. Currently, there is no predictive 
biomarker for entinostat for lung cancer treatment. Our 
preclinical studies using a panel of 17 lung cancer cell 
lines suggest that SALL4 could be a useful predictive 
marker for entinostat. Future clinical studies are needed 
to investigate whether SALL4 can be used as a biomarker 
in selecting lung cancer patients who may benefit from 
combination therapy with entinostat.
In summary, this is the first comprehensive study 
on the role of SALL4 in lung cancer. We have evaluated 
SALL4 expression in lung cancer in large cohorts 
of patients, and observed that SALL4 expression is 
upregulated in a subset (about 16%) of these patients 
including EGFR mutation negative cases. As reported in 
other types of cancers, SALL4 plays a critical role in lung 
cancer cell survival. This is supported by genetic (SALL4 
knockdown) and pharmacological (peptide) studies. 
SALL4-expressing lung cancer cells are more sensitive 
to entinostat treatment. Overall, our studies suggest that 
targeting SALL4 by entinostat is a novel approach for lung 
cancer treatment.
MATERIALS AND METHODS
Patient samples
173 cases of primary lung cancer tissues (52 SCC, 
100 ADC, and 21 BAC) and 166 cases of matched normal 
lung tissues from the archives of the National University 
Hospital, Singapore were included in this study. Ethics 
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approval was obtained from the National University of 
Singapore Institutional Review Board (NUS IRB 09-261).
Antibodies and reagents
All phospho-antibodies (pIGF1R #3024, pEGFR 
#2234, pAKT #9271, pMAPK #9101) and polyclonal 
antibodies to AKT (#9272) and IGF1R (#3027) were from 
Cell Signaling Technology (Beverly, MA). Monoclonal 
mouse antibodies to SALL4 (#sc-101147) and CBL-B 
(#sc-1705), and polyclonal antibody to EGFR (#sc-03) 
were from Santa Cruz Biotechnology (Santa Cruz, CA). 
Polyclonal antibody to MAPK (#61-7400) was from 
Invitrogen Life Technologies (Carlsbad, CA). HDAC 
inhibitors (trichostatin A and entinostat) were provided by 
Dr. James Bradner’s lab at DFCI.
Cell lines
Lung tumor cell lines (PC-9, H460, A549, H1299, 
H520, A427, H292, H441, H322, H1650, H1395, 
HCC827, H3122, H1975, H3255, and H23) and a normal 
lung epithelial cell line (Beas2B) were kindly provided by 
Drs. Daniel G. Tenen and Susumu Kobayashi. H522 and 
H661 cell lines were purchased from the American Type 
Culture Collection (ATCC).
SALL4 immunohistochemistry
IHC staining was performed according to the 
standard techniques as described previously [15].
Lentiviral SALL4 overexpression and SALL4 
shRNA constructs and lentivirus packaging
Human SALL4A or SALL4B fragments were 
subcloned into a modified lentiviral vector (FUW-Luc-
mCh-puro) with mCherry and puromycin selection markers. 
Lentivirus preparations were produced by cotransfecting 
empty vector pLKO.1puro with SALL4 shRNA or FUW 
with SALL4 ORF, and helper virus packaging plasmids 
pCMVΔR8.91 and pMD.G (at a 10:10:1 ratio) into 293T 
cells. Transfections were carried out using lipofectamine 
and PLUS reagent. Lentiviruses were harvested at 24, 
36, 48, and 60 hrs post-transfection, and frozen at -80oC 
in aliquots at appropriate amounts for infection. Validated 
shRNAs were used for SALL4 knockdowns. The sequences 
for SALL4 shRNA and scrambled shRNA are as follows: 
SALL4 shRNA: 5’-GCCTTGAAACAAGCCAAGCTA-3’; 
and Scr-shRNA: 5’-CCTAAGGTTAAGTCGCCCTCG-3’.
Cell culture and virus infection
H661, H522, PC-9, H292 and H1299 cell 
lines were maintained in RPMI1640 medium plus 
15% fetal bovine serum (FBS) containing penicillin/
streptomycin and L-glutamine. Beas2B was maintained 
in F10 containing 10% FBS, penicillin/streptomycin, 
L-glutamine, amphotericin, Mitotracker+, and bovine 
pituitary extract. Transduction was carried out as 
described previously48.
Cell viability analysis
Lung cancer cells were plated at 5,000 cells/well 
in a 96-well flat-bottomed plate (Falcon, Lincoln NJ) and 
cultured in RPMI1640 for 24 hours before transduction 
with lentiviral empty vector, SALL4 shRNA, or treatment 
with HDAC inhibitors (entinostat or TSA), or TAT-SALL4 
peptide (YGRKKRRQRRRMSRRKQAKPQHI)/TAT-con 
peptide(YGRKKRRQRRR). Cell viability was assessed 
1-5 days after transduction or inhibitor treatment using 
the MTT assay as described14, 22, 48. Data were normalized 
to the empty vector group or DMSO. All assays were 
performed in quadruplicate wells, and were averaged from 
two independent experiments for each cell line.
Foci formation assay
Lung cancer cells (H661) were treated with 
scrambled shRNA (Scr-sh) or SALL4 shRNA (SALL4-
sh). Three days after lentiviral transduction, cells were 
plated at 500 cells per well in a 6-well plate (Corning, 
NY) and cultured in RPMI1640 medium for 2 weeks. 
Colony formation was observed by staining with crystal 
violet solution (0.1% crystal violet/ 25% methanol) and 
the number of colonies was manually counted. All assays 
were performed in triplicate wells and averaged from two 
independent experiments.
Xenotransplant murine models
All experimental procedures involving animals were 
conducted in accordance with the institutional guidelines 
set forth by the Children’s Hospital Boston (CHB animal 
protocol number 11-09-2022). Eight to 10 week-old NOD/
SCID mice were housed in a specific pathogen-free facility. 
Athymic nude mice were injected subcutaneously with 
PC-9 cells expressing SALL4-targeting shRNA on one flank 
(n=3 each) and scramble shRNA control on the other flank 
(n=3). 2 × 106 infected cells on puromycin selection were 
resuspended in BD Matrigel and implanted subcutaneously 
at each injection site. After injection, mice were examined 
and tumor volumes were measured at various time points. 
Tumor volume was calculated by using the formula, tumor 
volume = (length × width× height)/2. Mice were killed by 
CO2 inhalation and necropsied 4 weeks after injection, and 
then tumor volume was evaluated.
Chromatin Immunoprecipitation (ChIP)-qPCR
H661 cells were cross-linked with 1% formaldehyde 
and snap-frozen until processed. 10 million cells were 
used per experiment. Cells were lysed in 1ml of cell lysis 
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buffer (20mM Tris, pH8/ 85mM KCl/ 0.5% NP-40 and 
1X cOmplete protease inhibitor cocktail), and the nuclei 
was resuspended in nuclear lysis buffer (10mM Tris-
HCl, pH7.5/ 1% NP-40/ 0.5% NaDOC/ 0.1% SDS/ 1X 
cOmplete protease inhibitor cocktail). The nuclei were 
then sonicated using the Biorupter (30s on/off pulses for 
10 cycles). The salt concentration of the sheared chromatin 
was adjusted to 500mM NaCl. Immunoprecipitations 
were then carried out with 1.9μg of SALL4 antibody in 
ChIP dilution buffer (16.7mM Tris-HCl, pH8.1/ 500mM 
NaCl/ 0.01% SDS/ 1.1% Triton X-100/ 1.2mM EDTA) 
overnight. Bead complexes were washed twice with RIPA 
buffer high salt (500mM), then twice with LiCl buffer 
(10mM Tris-HCl, pH8.1/ 1mM EDTA/ 1% NaDOC/ 1% 
NP-40/ 250mM LiCl), and finally twice in TE buffer. 
Protein-DNA complexes were then eluted with 100μl 
of ChIP elution buffer (10mM Tris-HCl, pH8/ 5mM 
EDTA/ 300mM NaCl/ 0.1% SDS) and 16μl of reverse-
crosslinking buffer (250mM Tris-HCl, pH6.4/ 1.25M 
NaCl/ 62.5mM EDTA/ 5mg/ml Proteinase k/ 62.5mg/ml 
RNAse A) by incubated at 65°C overnight. DNA samples 
were then PCR purified with QIAquick PCR Purification 
Kit (Qiagen, Germany) and analysed by qPCR. ChIP-
qPCR primers used were: CBLB promoter forward: 5’- 
CAGCATCAATAATACCCAAAATTCGACC-3’, reverse: 
5’- CGATGGAGGAAGATGCAGTGGTAC-3’.
Primers
The qRT-PCR assays for SALL4, EGFR, IGF1R and 
CBLB were performed using the following primers: SALL4 
sense: 5’-CCGTCCATGCGGAAGATC-3’ and anti-sense: 
5’-GAAGACCTCCTCCTCGCACT-3’; EGFR sense: 
5’-CCCCCAGCGTATCTATATGGAA-3’ and anti-sense: 
5’-GCTGTCCCTCTCCACTGCAA-3’; 5 IGF1R sense: 
5’-GAGAGCTGGTAGTTAGTAGCATGTTGA-3’ and anti-
sense: 5’- AATTCCAATAATGAACCCAATAGATTAGTTA 
-3’17. CBLB sense: 5’-GAGAGCTGGTAGTTAGTAGC
ATGTTGA-3’ and anti-sense: 5’- AATTCCAATAATGA 
ACCCAATAGATTAGTTA -3’. As controls, GAPDH was 
amplified using the following primers: GAPDH sense: 
5’-GAAGGTGAAGGTCGGAGTCAAC-3’ and anti-sense: 
5’-TGGAAGATGGTGATGGGATTTC-3’. All primers 
were obtained from Invitrogen. The comparative Ct (cycle 
threshold) method was used to determine RNA expression 
fold differences in lung cancer cell lines. The data points (run 
in triplicate assays) were normalized to GAPDH.
Microarray
Total RNA was extracted using Qiagen RNeasy 
Mini Kit (Qiagen, Hilden, Germany) following 
manufacturer’s instructions. RNA quantity was assessed 
using Nanodrop (Thermo Fisher Scientific, Wilmington, 
DE) and RNA integrity was analyzed using Nano chip 
for Eukaryotes on the Agilent 2100 Bioanalyzer (Agilent 
Technologies, Santa Clara, CA). A RIN value of 8.0 
and above was considered to indicate a satisfactory 
sample quality. Gene expression array was carried out 
as described previously48. The microarray data was 
deposited in the GEO database with the Accession 
number GSE68959.
GSEA analysis
Gene expression data of lung cancers was extracted 
from the GEO database (accession number: GSE31210 
and GSE19188). Before GSEA, all lung cancer samples 
were divided into two groups according to their SALL4 
expression levels: SALL4 high and SALL4 low. GSEA 
was then performed based on normalized data using 
GSEA v2.0 tool (http://www.broad.mit.edu/gsea/) for 
identification of enriched gene sets between the SALL4 
high and SALL4 low groups.
Statistical analysis
Results are expressed as mean ± s.d. from at least 
three independent experiments, unless otherwise stated. 
Statistical significance between the two groups was 
determined by Student’s t-test or Pearson’s Chi-squared 
(χ2) test (GraphPad Prism 5.0 software (La Jolla, CA, 
USA). Log-rank test was used for survival analysis. The 
value of P < 0.05 was considered statistically significant 
and is indicated by an asterisk.
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